Wells Fargo
BLTE

Wells Fargo’s Belite Bio BLTE Stock Holding History

Wells Fargo’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.1K Hold
124
– – ﹤0.01% 5934
2026
Q1 		$19.8K Buy
124
+24
+24% +$4.04K ﹤0.01% 5775
2025
Q4 		$16K Buy
+100
New +$11.8K ﹤0.01% 5847

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo's BLTE Position: Q2 2026 in Review

Wells Fargo held its Belite Bio (BLTE) position steady in Q2 2026 at 124 shares worth $19.1K. The position accounts for ﹤0.01% of the portfolio, ranked #5934.

Wells Fargo first reported a position in BLTE in Q4 2025 and has held it in 3 quarters since. The position peaked at $19.8K in Q1 2026. 80 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • Wells Fargo held 124 shares of Belite Bio worth $19.1K as of Q2 2026.
  • Wells Fargo left its Belite Bio share count unchanged in Q2 2026.
  • Belite Bio made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5934 holding.
  • Wells Fargo first reported a position in Belite Bio in Q4 2025 and has held it in 3 quarters since.
  • Wells Fargo's Belite Bio position peaked at $19.8K in Q1 2026.
  • 80 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.